MYGN today
$5.67-$0.01 (-0.18%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourDescending Triangle
1 hourExpanding
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns down below $5.25
Key levels
Resistance$6.75
Resistance$5.95
Support$5.55
Support$4.83
Latest news & SEC filings
AnalystStephens starts Myriad Genetics coverage with Hold rating
AnalystStephens & Co. keeps Equal-Weight on Myriad Genetics, lifts target to $6
SEC FilingMyriad Genetics Inc filed an insider trading report (Form 4)
All MYGN news →About Myriad Genetics
Myriad Genetics is a molecular diagnostics company that develops and sells genetic tests for cancer, prenatal, and mental health care. Its oncology products include hereditary cancer, companion diagnostic, and tumor profiling tests, while its women's health offerings cover prenatal screening and carrier testing. The company also provides pharmacogenomic testing to guide mental health medication selection. It sells primarily in the United States and Japan, with additional reach through partners in Europe and Asia-Pacific.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
MYRIAD GENETICS INC (MYGN)
What Is the Price Target for MYGN?
SEPT Low Target
$3.06
SEPT Mid Target
$3.60
SEPT High Target
$4.14
Analyst Consensus
$3.60
Is MYGN a Buy or Sell Right Now?
Thesis
- •Revenue growing -1.6% YoY with SLOWING trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MYGN.
Start Free Trial →Is MYGN Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$3.70
31
Moat Score
NONE
5/9
Piotroski Score
-1.8
Altman Z-Score
What Is Smart Money Doing with MYGN?
Insider Signal
NEUTRAL
1 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Wheeler Benjamin Richard | officer | Sale | 2,555 | $10K | Sep 21, 2026 |
| Fox Jennifer Lynne | officer | Sale | 4,398 | $14K | Sep 3, 2026 |
| Donnelly Brian J | officer | Buy | 5,000 | $20K | Jun 11, 2026 |
| Raha Samraat S. | director officer | Buy | 3,542 | $14K | Jun 11, 2026 |
| Kumar Rashmi | director | Sale | 15,000 | $67K | Jun 8, 2026 |
| Davis Mark Steven | director | Buy | 59,701 | - | Jun 4, 2026 |
| Kumar Rashmi | director | Buy | 59,701 | - | Jun 4, 2026 |
| Newcomer Lee Nisley | director | Buy | 59,701 | - | Jun 4, 2026 |
| Reitan Colleen F | director | Buy | 59,701 | - | Jun 4, 2026 |
| Skovronsky Daniel | director | Buy | 59,701 | - | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MYGN Growth Story
Revenue YoY
-1.6%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-180.14%
FCF Growth YoY
N/A%
Revenue Trend
SLOWING
Dark Pool Trades for MYGN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MYGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:06:13 | $5.67 | 7,938 | $$45K | MIDPOINT |
| 18:46:06 | $5.63 | 9,580 | $$54K | SELL |
| 18:44:16 | $5.64 | 7,772 | $$44K | BUY |
| 18:27:41 | $5.63 | 8,478 | $$48K | MIDPOINT |
| 18:12:02 | $5.59 | 3,900 | $$22K | BUY |
5 dark pool trades shown · $$212K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MYRIAD GENETICS INC (MYGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MYGN — frequently asked questions
What is MYGN stock price today?
MYRIAD GENETICS INC (MYGN) is at $5.67, down 0.18% (-$0.01) at the Nov 13, 2026 close.
Why is MYGN stock moving today?
Latest MYGN news — Nov 13, 2026: Stephens starts Myriad Genetics coverage with Hold rating · Nov 12, 2026: Stephens & Co. keeps Equal-Weight on Myriad Genetics, lifts target to $6
What is the MYGN price target?
The average analyst price target for MYGN is $3.60, ranging from $3 to $8, based on 5 analysts. Latest: TD Cowen maintains on Oct 13, 2026.
What do analysts rate MYGN?
Analyst ratings for MYGN: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did MYGN beat earnings?
MYGN last reported on Jul 30, 2026: EPS -$0.25 vs -$0.06 expected — a miss of 331.8%.
Does MYGN pay a dividend?
MYGN does not currently pay a dividend.
How much debt does MYGN have?
MYRIAD GENETICS INC reported $121M of debt and $115M of cash (Jun 30, 2026).
What are MYGN support and resistance levels?
Support: $5.55, $4.83, $4.40. Resistance: $5.95, $6.75, $7.15.
What are insiders doing with MYGN?
Insider activity: NEUTRAL, 1 buys and 1 sells in the last 90 days.
What is the latest news on MYGN?
Nov 13, 2026: Stephens starts Myriad Genetics coverage with Hold rating · Nov 12, 2026: Stephens & Co. keeps Equal-Weight on Myriad Genetics, lifts target to $6 · Nov 9, 2026: Myriad Genetics Inc filed an insider trading report (Form 4)